Atea Pharmaceuticals, Inc.
Clinical trials sponsored by Atea Pharmaceuticals, Inc., explained in plain language.
-
New hep c combo aims to match top therapy in phase 3 showdown
Disease control OngoingThis study tests a new two-drug combination, BEM/RZR, against an approved treatment, SOF/VEL, in 880 adults with chronic hepatitis C. The goal is to see if BEM/RZR can clear the virus as effectively and safely. Participants must not have taken prior HCV drugs and may have compens…
Phase: PHASE3 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hepatitis c pill aims to cut treatment time in half
Disease control OngoingThis Phase 3 trial compares a new two-drug combination pill (Bemnifosbuvir-Ruzasvir) against the current standard treatment (Sofosbuvir-Velpatasvir) for adults with chronic hepatitis C. About 880 participants who have not been treated with similar drugs before will take the new p…
Phase: PHASE3 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC